Vertex to acquire Alpine Immune Sciences for $4.9 bln
April 10 (Reuters) - Vertex Pharmaceuticals VRTX.O will acquire Alpine Immune Sciences ALPN.O for $65 per share, or about $4.9 billion in cash, the companies said on Wednesday. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Alpine Immune Sciences
See all newsAlpine Immune Sciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Alpine Immune Sciences Q1 EPS USD -0.28 Vs. IBES Estimate USD -0.41
Moves: Lazard hires veteran healthcare dealmaker Colocci as vice chairman
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
US STOCKS-S&P 500, Nasdaq end sharply higher on soft inflation data, eyes on earnings